ASCO 2023 What To Expect How We Can Help Team Location What’s On-Board The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare ...
home/conference/asco The Importance of Treatment Sequencing in Mantle Cell Lymphoma Mary Caffrey;Maggie L. Shaw July 16th 2024 We recently spoke with Tycel Phillips, MD, associate professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, about his...
除了KROCUS联合研究,氟泽雷塞单药治疗KRAS G12C突变晚期NSCLC也有良好表现。 在2023年欧洲肿瘤内科学会亚洲大会(ESMO Asia)上,吴一龙教授汇报了氟泽雷塞针对我国NSCLC患者的一项临床II期注册研究。初步研究结果显示,氟泽雷塞治疗KRAS G12C突变...
International Association for the Study of Lung Cancer (IASLC) Chair, 2005 World Conference on Lung Cancer European Society for Medical Oncology (ESMO) Member, Scientific Program Sub-Committee (NSCLC, metastatic)for ESMO Annual Congress European Organization for Research and Treatment of Cancer (EORTC)...
总之，洛拉替尼展示了卓越的疗效，预计将成为ALK阳性NSCLC患者的一线治疗标准。图1 洛拉替尼（Lorbrena，...
By The ASCO Post Staff/2024 NCCN Annual Conference Natalie S. Callander, MD, on Multiple Myeloma: Management Updates Natalie S. Callander, MD, of the University of Wisconsin Carbone Cancer Center, discusses advances in the treatment of patients with multiple myeloma, including her commentary on sm...
2023年美国临床肿瘤学会泌尿男生殖系肿瘤研讨会报道的多项研究进展对临床选择前列腺癌治疗方案有重要指导意义.依据人群特性开展精准化的多联疗法已成为前列腺癌治疗的主流趋势,包括转移性激素敏感性前列腺癌中的三药联合治疗及转移性去势抵抗性前列腺癌中的多腺苷二磷酸核糖聚合酶抑制剂联合治疗.此外,核素治疗和放疗也受到...
Joshua G. Cohen, MD, Associate Clinical Professor in the Department of Surgery and Medical Director of the Orange County Gynecologic Cancer Program at City of Hope, Orange County, California, shared h... Gynecologic Cancers By The ASCO Post Staff/May 25, 2023 - Supplement: Conference Highlights...
As the discussion expert at this conference, you discussed the two studies in Oral Abstract Session B, can you share with us the main background of these two studies and why you think they were so important? Dr. Ll...
(BlissBio) will present a poster at the conference with results from the first-in-human study of BB-1701, a HER2-targeting ADC (Abstract #3029). Eisai entered into a joint development agreement with BlissBio for BB-1701 with option rights for a ...